REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Macquarie Group Ltd.

Macquarie Group Ltd. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,332 shares of the biotechnology company’s stock after selling 759 shares during the period. Macquarie Group Ltd. owned approximately 0.34% of REGENXBIO worth $3,967,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of REGENXBIO by 0.3% during the first quarter. BlackRock Inc. now owns 6,588,815 shares of the biotechnology company’s stock worth $218,683,000 after purchasing an additional 17,377 shares during the last quarter. Vanguard Group Inc. lifted its holdings in REGENXBIO by 0.4% in the first quarter. Vanguard Group Inc. now owns 4,070,462 shares of the biotechnology company’s stock worth $135,099,000 after acquiring an additional 16,496 shares during the last quarter. State Street Corp lifted its holdings in REGENXBIO by 5.6% in the second quarter. State Street Corp now owns 2,801,494 shares of the biotechnology company’s stock worth $69,197,000 after acquiring an additional 147,728 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in REGENXBIO by 16.4% in the third quarter. Dimensional Fund Advisors LP now owns 1,254,101 shares of the biotechnology company’s stock worth $33,142,000 after acquiring an additional 176,607 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in REGENXBIO by 9.7% in the second quarter. Point72 Asset Management L.P. now owns 567,500 shares of the biotechnology company’s stock worth $14,017,000 after acquiring an additional 50,233 shares during the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Trading Down 2.0 %

NASDAQ RGNX opened at $22.97 on Thursday. REGENXBIO Inc. has a 12 month low of $18.69 and a 12 month high of $35.73. The company’s 50 day simple moving average is $22.88 and its 200 day simple moving average is $23.78.

REGENXBIO (NASDAQ:RGNX – Get Rating) last posted its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.10. The firm had revenue of $31.35 million for the quarter, compared to analyst estimates of $37.45 million. REGENXBIO had a negative net margin of 248.68% and a negative return on equity of 45.51%. The firm’s quarterly revenue was down 92.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.67 earnings per share. As a group, analysts predict that REGENXBIO Inc. will post -4.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $61.00 target price on shares of REGENXBIO in a report on Thursday, March 2nd. Morgan Stanley dropped their price target on shares of REGENXBIO from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, SVB Leerink dropped their price target on shares of REGENXBIO from $15.00 to $14.00 and set a “market perform” rating on the stock in a research note on Monday, January 23rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.86.

About REGENXBIO

(Get Rating)

REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.